vs
Side-by-side financial comparison of EXPONENT INC (EXPO) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $166.3M, roughly 1.8× EXPONENT INC). EXPONENT INC runs the higher net margin — 17.8% vs 12.8%, a 4.9% gap on every dollar of revenue. On growth, EXPONENT INC posted the faster year-over-year revenue change (14.3% vs -6.4%). Over the past eight quarters, EXPONENT INC's revenue compounded faster (8.8% CAGR vs 4.2%).
Exponent, Inc. is an American engineering and scientific consulting firm. Exponent has a team of scientists, physicians, engineers, and business consultants which performs research and analysis in more than 90 technical disciplines. The company operates 20 offices in the United States and five offices overseas.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
EXPO vs TECH — Head-to-Head
Income Statement — Q1 FY2027 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $166.3M | $295.9M |
| Net Profit | $29.6M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | 24.9% | 18.4% |
| Net Margin | 17.8% | 12.8% |
| Revenue YoY | 14.3% | -6.4% |
| Net Profit YoY | 11.0% | 68.3% |
| EPS (diluted) | $0.59 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $166.3M | — | ||
| Q4 25 | $147.1M | $295.9M | ||
| Q3 25 | $142.0M | — | ||
| Q2 25 | $145.5M | $317.0M | ||
| Q1 25 | $136.8M | $316.2M | ||
| Q4 24 | — | $297.0M | ||
| Q3 24 | $136.3M | $289.5M | ||
| Q2 24 | $140.5M | $306.1M |
| Q1 26 | $29.6M | — | ||
| Q4 25 | $28.0M | $38.0M | ||
| Q3 25 | $26.6M | — | ||
| Q2 25 | $26.6M | $-17.7M | ||
| Q1 25 | $23.6M | $22.6M | ||
| Q4 24 | — | $34.9M | ||
| Q3 24 | $26.0M | $33.6M | ||
| Q2 24 | $29.2M | $40.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | 24.9% | — | ||
| Q4 25 | 19.7% | 18.4% | ||
| Q3 25 | 12.1% | — | ||
| Q2 25 | 30.5% | -7.5% | ||
| Q1 25 | 19.9% | 12.2% | ||
| Q4 24 | — | 16.0% | ||
| Q3 24 | 19.0% | 13.8% | ||
| Q2 24 | 25.4% | 15.0% |
| Q1 26 | 17.8% | — | ||
| Q4 25 | 19.1% | 12.8% | ||
| Q3 25 | 18.7% | — | ||
| Q2 25 | 18.3% | -5.6% | ||
| Q1 25 | 17.2% | 7.1% | ||
| Q4 24 | — | 11.7% | ||
| Q3 24 | 19.1% | 11.6% | ||
| Q2 24 | 20.8% | 13.3% |
| Q1 26 | $0.59 | — | ||
| Q4 25 | $0.55 | $0.24 | ||
| Q3 25 | $0.52 | — | ||
| Q2 25 | $0.52 | $-0.11 | ||
| Q1 25 | $0.45 | $0.14 | ||
| Q4 24 | — | $0.22 | ||
| Q3 24 | $0.50 | $0.21 | ||
| Q2 24 | $0.57 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $118.6M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $338.3M | $2.0B |
| Total Assets | $687.4M | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $118.6M | — | ||
| Q4 25 | $207.4M | $172.9M | ||
| Q3 25 | $231.8M | — | ||
| Q2 25 | $245.1M | $162.2M | ||
| Q1 25 | $258.9M | $140.7M | ||
| Q4 24 | — | $177.5M | ||
| Q3 24 | $219.7M | $187.5M | ||
| Q2 24 | $203.3M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | $338.3M | — | ||
| Q4 25 | $402.9M | $2.0B | ||
| Q3 25 | $427.8M | — | ||
| Q2 25 | $441.4M | $1.9B | ||
| Q1 25 | $421.1M | $2.0B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | $410.3M | $2.1B | ||
| Q2 24 | $393.2M | $2.1B |
| Q1 26 | $687.4M | — | ||
| Q4 25 | $761.4M | $2.5B | ||
| Q3 25 | $759.4M | — | ||
| Q2 25 | $763.2M | $2.6B | ||
| Q1 25 | $777.3M | $2.6B | ||
| Q4 24 | — | $2.7B | ||
| Q3 24 | $744.1M | $2.7B | ||
| Q2 24 | $709.2M | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXPO
| Revenues before reimbursements | $151.8M | 91% |
| Reimbursements | $14.5M | 9% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
